Capnopharm develops aerosol-based chemotherapies and immunotherapies for peritoneal and pleural cancer patients.
The company’s science relies on evidence around PIPAC, a minimally invasive aerosol drug delivery system. Capnopharm explores drug-device synergies with pharmaceutical clients.
Based on the company’s public LinkedIn information, supplied through RevenueBase.
Research and development spans reformulation of existing chemotherapy drugs and next-generation drugs involving nanoparticles, DNA, mRNA or immunotherapeutics.
Source: LinkedIn company description · Retrieved October 13, 2026
Supported appearances on published RevenueBase lists, including available memberships beyond displayed rankings.
Positions describe ordering within each source list. See how lists are built ↗
Embeddable award for your website
Open the published source list.RevenueBase prepared this profile from the company’s public LinkedIn information and RevenueBase company data. These source records were retrieved on October 13, 2026. AI helped summarize these sources, with a separate automated check against the source text completed on November 3, 2026. Directory positions use company-contact counts from separate saved list snapshots dated September 18, 2026 and September 21, 2026. How the company lists are built.
Share a correction, your relationship to the company, and supporting sources. Requests are reviewed before changes are published.
Explore more companies by name, headquarters and business focus.